2 Red-Hot Drug Stocks Squeezing Shorts

The FDA approved Esperion's cholesterol drug marketing applications

Managing Editor
May 6, 2019 at 9:55 AM
facebook twitter linkedin


Near the top of the Nasdaq today sits Esperion Therapeutics Inc (NASDAQ:ESPR), after the Food and Drug Administration (FDA) accepted marketing applications for the company's cholesterol drug. At last check, ESPR is up 13% to trade at $48.86, on track for its best day since Oct. 26. The good news was met with a generous price-target hike to $90 from $79 at Credit Suisse, territory not seen since July 2015. 

Today's surge has the shares toppling their year-to-date breakeven level, and hurtling past resistance at their 200-day moving average. This trendline had kept a lid on rallies since a mid-March bear gap. 

A short squeeze could keep the wind at the equity's back. Short interest dropped by 13.6% in the two most recent reporting periods to 4.69 million shares. Yet this still accounts for a whopping 21.6% of the stock's total available float, and 8.3 days of pent-up buying power, at the average pace of trading. 

Then there's Axsome Therapeutics Inc (NASDAQ:AXSM), up 3.7% to trade at $18.61, and earlier nabbing a new record high of $19.25. The company announced it had expedited development programs for both its depression drug and migraine treatment.

It's been nothing short of a meteoric rise for AXSM. For reference, the shares closed at $2.82 on Dec. 31, and have only turned in four weekly losses in 2019. Since March, pullbacks have found support at the stock's ascending 20-day moving average.

Axsome could soon squeeze shorts, too. Despite the stock's climb, short interest increased by 37.4% in the two most recent reporting periods to 5.27 million shares, a new record high. This takes up 27.6% of AXSM's total available float, and is 5.6 times the average daily trading volume.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners